Translation is an essential cellular process whose deregulation is associated with alterations in cell growth regulation, cell cycle progression, and apoptotic responses. There is much evidence supporting the notion that aberrant control of protein translation contributes to neoplastic transformation. Signaling pathways (e.g. - ras and Akt) that regulate the translational machinery are activated in many human cells, over-expression of certain translation factors can lead to malignant transformation, and several components of the translational apparatus are over-expressed in human cancers. Indeed, elevated expression levels of elF4E (the mRNA cap binding protein involved in ribosome recruitment) leads to transformation in murine cancer model and is implicated in chemoresistance. Rapamycin, an inhibitor of the ribosome recruitment step, shows significant anti-cancer activity and is currently being tested in clinical trials. In this grant application, we propose to develop a series of HTS assays that will form the foundation of a chemical biology program aimed at better understanding the mechanism of translation, as well as the role that deregulation of this process plays in tumor progression. The HTS assays will target translation initiation factors involved in eukaryotic ribosome recruitment and will be used to identify compounds that can specifically inhibit this process.
Our specific aims are to: i) target the interaction between elF4E and the mRNA cap structure for HTS assay design; ii) develop an HTS assay that monitors the helicase activity of elF4A, an ATP-dependent RNA helicase that unwinds mRNA secondary structure in the 5' UTR of mRNAs; iii) develop an HTS assay for inhibitors of elF4B activity, an RNA binding factor that functions in conjunction with elF4A to facilitate mRNA/ribosome binding; and iv) develop an HTS assay to prevent formation of the elF4E/4E-BP inhibitory complex, a heterodimer whose formation is stabilized by rapamycin.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Drug Discovery and Molecular Pharmacology Study Section (DMP)
Program Officer
Arya, Suresh
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mcgill University
Zip Code
H3 0-G4
Cencic, Regina; Desforges, Marc; Hall, David R et al. (2011) Blocking eIF4E-eIF4G interaction as a strategy to impair coronavirus replication. J Virol 85:6381-9
Cencic, Regina; Hall, David R; Robert, Francis et al. (2011) Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F. Proc Natl Acad Sci U S A 108:1046-51
Sukarieh, R; Sonenberg, N; Pelletier, J (2009) The eIF4E-binding proteins are modifiers of cytoplasmic eIF4E relocalization during the heat shock response. Am J Physiol Cell Physiol 296:C1207-17
Galicia-Vazquez, Gabriela; Lindqvist, Lisa; Wang, Xiaofeng et al. (2009) High-throughput assays probing protein-RNA interactions of eukaryotic translation initiation factors. Anal Biochem 384:180-8
Cencic, Regina; Robert, Francis; Pelletier, Jerry (2007) Identifying small molecule inhibitors of eukaryotic translation initiation. Methods Enzymol 431:269-302
Cencic, Regina; Yan, Yifei; Pelletier, Jerry (2007) Homogenous time resolved fluorescence assay to identify modulators of cap-dependent translation initiation. Comb Chem High Throughput Screen 10:181-8
Bordeleau, Marie-Eve; Mori, Ayaka; Oberer, Monika et al. (2006) Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A. Nat Chem Biol 2:213-20
Bordeleau, Marie-Eve; Cencic, Regina; Lindqvist, Lisa et al. (2006) RNA-mediated sequestration of the RNA helicase eIF4A by Pateamine A inhibits translation initiation. Chem Biol 13:1287-95
Robert, Francis; Kapp, Lee D; Khan, Shakila N et al. (2006) Initiation of protein synthesis by hepatitis C virus is refractory to reduced eIF2.GTP.Met-tRNA(i)(Met) ternary complex availability. Mol Biol Cell 17:4632-44